Widely used:Recently Viewed
Clear AllQuality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$4,202 Mln
P/E Ratio
--
P/B Ratio
0.66
Industry P/E
--
Debt to Equity
0.75
ROE
-0.05 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
-1.39
CFO
$3,285.00 Mln
EBITDA
$4,526.00 Mln
Net Profit
$928.00 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Bausch + Lomb Corp (BLCO)
| -36.05 | 1.32 | -30.59 | -21.80 | -13.30 | -- | -- |
|
BSE Sensex
| 3.94 | 8.21 | 6.82 | 11.75 | 15.49 | 20.50 | 11.55 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
|
|---|---|
|
Bausch + Lomb Corp (BLCO)
| 9.99 |
|
S&P Small-Cap 600
| 13.89 |
|
BSE Sensex
| 18.74 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 4.11 | 139.15 | -- | -57.84 | |
| 6.75 | 257.30 | 23.25 | 9.19 |
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision... Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provides optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc. Address: 520 Applewood Crescent, Vaughan, ON, Canada, L4K 4B4 Read more
Executive VP & CFO
Mr. Osama A. Eldessouky
CEO & Chairman
Mr. Brenton L. Saunders J.D.
Headquarters
Vaughan, ON
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Bausch + Lomb Corp (BLCO) stood at $ 15,154 Mln as on 31-Mar-25
The share price of Bausch + Lomb Corp (BLCO) is $11.55 (NYSE) as of 14-May-2025 12:34 EDT. Bausch + Lomb Corp (BLCO) has given a return of -13.3% in the last 3 years.
Bausch + Lomb Corp (BLCO) has a market capitalisation of $ 4,202 Mln as on 13-May-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Bausch + Lomb Corp (BLCO) is 0.66 times as on 13-May-2025, a 70% discount to its peers’ median range of 2.19 times.
Since, TTM earnings of Bausch + Lomb Corp (BLCO) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Bausch + Lomb Corp (BLCO) and enter the required number of quantities and click on buy to purchase the shares of Bausch + Lomb Corp (BLCO).
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provides optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc. Address: 520 Applewood Crescent, Vaughan, ON, Canada, L4K 4B4
The CEO & director of Mr. Osama A. Eldessouky. is Bausch + Lomb Corp (BLCO), and CFO & Sr. VP is Mr. Brenton L. Saunders J.D..
There is no promoter pledging in Bausch + Lomb Corp (BLCO).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
35
|
|
|
23
|
|
|
35
|
|
|
23
|
| Bausch + Lomb Corp (BLCO) | Ratios |
|---|---|
|
Return on equity(%)
|
-7.71
|
|
Operating margin(%)
|
-2.45
|
|
Net Margin(%)
|
-10.16
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Bausch + Lomb Corp (BLCO) was $0 Mln.
$-0.21
(
